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A B S T R A C T
Data on the radiobiological effects of thermal neutrons are usually obtained from irradiations in a mixed field of
neutrons of different energies and gamma rays or from conversion of proton data with similar energies to those
created in the neutron capture on nitrogen. Experimental data from irradiations in a pure thermal or cold
neutron beam can help to find new values for neutron relative biological effectiveness (RBE) factors, which are
useful for BNCT (Boron Neutron Capture Therapy) and radiation protection applications. We present a new
experimental setup for radiobiological studies at a cold neutron beam at Institut Laue-Langevin, a beam without
fast neutron component and almost no gamma ray contribution. After the irradiation, survival assays are per-
formed to obtain the survival curves. Finally, comparing with a reference photon irradiation, the thermal
neutron RBE factors can be calculated. The methodology is outlined at the example of A375 melanoma cells for
which new radiobiological data were obtained.
1. Introduction
The estimation of the biological damage produced by neutrons is
not an easy problem to solve. As neutrons ionize indirectly, the key
point for the biological study is the effect of the secondary particles
after the collisions and nuclear reactions produced by them in the
tissue, which depend on the neutron energy. The knowledge of biolo-
gical damage of neutrons is useful for radioprotection, but also a key
factor for therapies with neutrons like Boron Neutron Capture Therapy
(BNCT).
BNCT is an experimental form of selective radiotherapy which is
currently regaining interest because of the most recent promising
clinical trials [1], and the development of new in-hospital accelerator-
based neutron sources that may bring this therapy closer to the clinical
practice [2].
Treatment planning in BNCT is based on figures of the so-called
weighted (or photon equivalent) dose. This is obtained by weighting the
different absorbed dose components by means of relative biological
effectiveness (RBE) weighting factors, usually denoted by wi, such that
the weighted dose DW is given by= + + +D w D w D w D w DW f f t t B B (1)
The dose components are [3,4]: the fast dose, Df , from the
secondary particles produced by neutrons with energy above 0.5 eV, i.e.
mainly hydrogen recoils; the thermal dose, Dt, by neutrons with energy
below 0.5 eV, mainly due to neutron capture on nitrogen, but excluding
capture on boron ; the boron dose, DB, due to the products of the boron
capture reaction, mostly from thermal neutrons, and the gamma dose,
D , which includes photons both from contamination of the beam and
from radiative captures produced in the tissue. The weighting factors,
wi, are obtained from a comparison between the dose given by the
neutrons and a reference photon dose, for a specific survival. No sy-
nergies between the different components are included.
The weighting factors currently used have been those proposed by
Coderre and Morris [5], based on radiobiology experiments focused on
the application to brain tumors [6]. Thus, the weighting factor for the
dose components in tumors are taken from the values obtained for
clonogenic assays of the rat 9L gliosarcoma. These values have also
been applied in other clinical BNCT trials, for instance with head and
neck cancers and melanoma, pending direct validation by means of new
experimentation with different tissues and/or cell types.
Moreover, in the experiments mentioned above, the irradiations
were performed with a mixed beam containing both fast and thermal
neutrons, which means that their effects could not be distinguished [7].
The neutron spectra of some of these beams are shown in Fig. 1. It has
been argued that the thermal and fast neutron weighting factors are
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similar due to comparable energy of the recoil proton from the elastic
collisions of the fast neutrons and the energy of the protons released
from the thermal neutron capture on nitrogen (584 keV) [5]. For this
reason, wf and wt have been considered equal in all the clinical trials
performed so far. However, more recent studies with protons of similar
energies as those coming from the two processes suggest that this as-
sumption should be reviewed [8].
The weighting factor, wt (as well as the boron dose weighting factor,
wB), is a factor independent of the neutron beam spectrum. Its accurate
determination is very important as it can be used at any BNCT facility,
whilst the fast neutron factor could depend on the particular beam
spectrum. Radiobiology studies with epithermal beams have shown a
strong energy-dependence [9,10], therefore the fast neutron RBE
should be measured at each BNCT facility. But even for the measure-
ment of wf itself from an epithermal neutron beam, prior knowledge of
the wt factor is required for correcting the effect of the neutrons that
thermalize in the sample.
Thermal neutron data can be obtained at reactors providing thermal
neutron beams from tangential beam tubes facing the water moderator
(either in the pool or tank) or so-called thermal columns. These are
beam tube inserts from e.g. graphite, that provide a well-thermalized
neutron spectrum, like at the BMRR reactor in Brookhaven [11] or
LENA in Italy [12]. However, even such beams are accompanied by a
non-negligible gamma component due to neutron captures in the
moderator as well as Compton scattered energetic gamma rays from the
reactor core. Differential measurements of the radiobiological effect of
neutrons alone are therefore challenging and intrinsically affected by
larger uncertainties from the background deduction, which cannot be
linearly subtracted as the photon biological effect is known to be de-
scribed by a linear-quadratic model.
Few high flux reactors and spallation neutron sources are equipped
with so-called neutron guides where neutrons are efficiently trans-
ported over large distances by total reflection on a vacuum-matter in-
terface. These neutron guides are slightly bent to prevent a direct view
on the source. Only thermal and slower neutrons can follow the cur-
vature by total reflection while faster neutrons and gamma rays go
straight and are stopped in the shielding of the neutron guide. Thus, at
the exit of such guides the initial component of epithermal and fast
neutrons as well as gamma rays from the reactor are completely sup-
pressed. Some background is still produced locally by interactions of
the neutron beam, but when taking care in the selection of beam win-
dows (separating the vacuum of the neutron guide from the experi-
mental setup), beam stop (downstream of the setup) and surrounding
material, the total background from gamma rays and fast neutrons can
be minimized. Certain reactors are equipped with a so-called cold
source where a vessel containing e.g. liquid deuterium (25 K) is in-
troduced on purpose to moderate neutrons to a lower energy. Beam
tubes facing such a cold source will extract cold neutrons, corre-
sponding to average neutron energies of few meV, i.e. lower than
thermal energies. Due to larger critical angles cold neutrons can be
more efficiently guided than thermal neutrons and higher beam in-
tensities are available for experiments.
One such beam, called PF1b, exists at Institut Laue-Langevin (ILL) in
Grenoble. Experiments that study nuclear reactions induced by neutron
capture or the effects thereof are performed there. For nearly all neu-
tron capture reactions the cross-section follows at low energies (thermal
and below) a perfect 1/v behavior, where v is the neutron velocity.
Therefore, cold neutrons can fully replace thermal neutrons as long as
the so-called thermal-equivalent capture flux (or just capture flux) is
used, expressed in nth/cm2s (see Fig. 1). For comparison with other
experiments using “true” thermal neutron beams we will use in the
following the term “thermal neutron effects” for our results, although
technically speaking they have been obtained at a cold neutron beam.
In this work, we show a procedure for using the PF1b line at ILL for
the irradiation of cells with a very pure thermal-equivalent neutron
beam. Without fast neutrons or gamma rays coming from the beam, this
line will allow the determination of the RBE factor with less un-
certainly, as the only non-desired gamma contribution comes from the
(unavoidable) photons produced in the sample, which will be mini-
mized in our set-up.
A demonstration of the ability to perform accurate measurement of
the wt factor will be shown in a test case, the A375 human melanoma
cell line. This is a relevant test case because it corresponds to a cell line
sufficiently different from rat gliosarcoma from which the accepted
values were taken [6], while it is still representative of an actual ap-
plication of BNCT.
Fig. 1. Neutron spectra of some BNCT beams [13] in comparison with the ILL Pf1b cold neutron beam. ILL data corresponds to the beam in June 2018 with a total
capture equivalent flux of n cm s1.75 10 /th9 2 measured.
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2. Materials and methods
2.1. The cold neutron line PF1b
The reactor at Institut Laue-Langevin is equipped with so-called
neutron guides where neutrons are efficiently transported over large
distances by total reflection on a vacuum-matter interface. As men-
tioned above, the PF1b cold neutron line [14] has been chosen for the
irradiation of cells because the absence of contamination from both
gammas and fast neutrons due to its bent guide.
The capture flux is determined by an activation experiment, of e.g. a
thin gold foil (12–14 μm). As this reaction follows a 1/v behavior one
uses the thermal 197Au(n,γ)198Au cross-section of 98.7b to derive from
the measured 198Au activity the capture flux. Irrespective of the exact
neutron spectrum the number of neutron captures in thin samples will
always correspond to that in a pure thermal neutron beam of the same
capture flux. For a cold neutron beam of 4meV average energy the
average neutron velocity is 880m/s, i.e. a factor 2.5 smaller compared
to a thermal neutron beam with 25meV average energy and average
neutron velocity of 2200m/s.
While the number of captures in a thin sample is perfectly described
by the capture flux, it is evident that there will be less neutrons passing
per cm2 per second than for a true thermal beam. The actual particle
flux is smaller by the very same factor 2.5 as the cross-section is larger
than the thermal cross-section. If very thick samples are used, cold
neutron beams experience a stronger attenuation than thermal neutrons
and they also change their spectrum (“beam hardening”) due to more
pronounced attenuation of slower neutrons and partial up-moderation
to the temperature of the sample. Ultimately, for infinitely thick sam-
ples, the particle flux determines the total number of captures per
second and not the capture flux.
The experiments described in the following represent an inter-
mediate of both cases: the cell layer represents a thin sample where the
number of captures and, thus, the radiobiological effects of the neu-
trons, are very well described by the capture flux. When a stack of
multiple vials with individual cell layers is used, the actual neutron
spectrum has to be considered to determine the attenuation of the
neutron flux from one vial to the next while for the number of captures
in every cell layer again the local capture flux is used. The attenuation
calculation has been performed by Monte Carlo simulations with the
MCNPX code and validated by gold foil activations placed at the re-
spective positions of cell layers.
The initial beam leaving the PF1b neutron guide was collimated by
a 3m long set of 10B and 6Li containing diaphragms to obtain a pencil-
like beam of 2 cm diameter (Fig. 2). All boron diaphragms were dou-
bled with 5 cm thick lead diaphragms to avoid gamma contamination of
the beam. All diaphragms close to the sample and the beam stop were
made from 6LiF to prevent gamma background. Without samples pre-
sent, the capture flux at the sample position, measured by gold foil
activation, was 1.8x109 nth/cm2s. Therefore, with the bent guide and
the collimation system, that results in a gamma background of less than
2% of the beam, the gamma component will be due to the set-up
components situated after the collimation (samples and sample holders)
The beam alignment and homogeneity was checked by radio-
chromic films (Gafchromic EBT2). Films were irradiated at different
irradiation times to calibrate the grey level as function of capture flu-
ence. Subsequently, the grey levels across the beam spot were analyzed
to check the homogeneity of the beam. Deviations from the average flux
are on average less than 2%, see Fig. 4. A detailed description of a very
similar collimation system used for prompt gamma ray spectroscopy at
the PF1b beam line can be found in [15]. The present collimation
system used wider diaphragms (20mm diameter instead of 12mm)
over a shorter distance (2.5m instead of 5m) leading to a significantly
higher capture flux at the target position.
In Fig. 3 both the simulated particle flux and capture flux at the exit
of the collimator system at PF1b line are displayed.
2.2. Irradiation Set-up
Cells are placed in 100-QS 2mm Hellma Suprasil absorbance quartz
cuvettes. This hydrogen-free vessel minimizes neutron scattering while
the neutron capture cross-sections in silicon and oxygen are small en-
ough to minimize production of gamma rays in the material. The cuv-
ettes have a 2mm empty space which is used to place the cells with
minimal amount of culture medium (200 μl). To assure a thin cell layer
on a well-defined side of the cuvette, the cuvette is placed horizontally
for 24 h after filling. The low thickness of the cuvette allows keeping the
medium at the bottom, even when the cuvette is placed horizontally.
Any adherent cell type will thus attach just to the bottom side.
For the irradiation, the quartz cuvettes are filled with fresh media
and placed upright in a Teflon holder with the side of the adhering cell
layer facing the beam (see Fig. 3). Two samples are irradiated at the
same time, where the downstream one receives about half of the dose
compared to the first one. This allows obtaining two survival points per
irradiation time. Although the relative gamma dose component (in our
experiments mainly due to the capture on hydrogen in the medium and
in the cells) increases from the first to the second cuvette, it is still
smaller than the neutron dose component (see Table 2). The scheme of
the setup is illustrated in Fig. 5.
The doses received by both cell layers are estimated by means of a
Monte Carlo simulation performed with the MCNPX code [16] using the
neutron beam spectrum, the set-up geometry and the corresponding
materials. The neutron spectrum after the collimation system was
Fig. 2. Collimation system situated at the end of the bent guide. The neutron
beam at the end of the collimation is 2 cm in diameter. Secondary gammas
created by captures on boron collimators are stopped in the lead layers. The last
collimator is made from LiF to capture neutrons without secondary gamma
emission.
Fig. 3. PF1b beam spectrum (red) and the spectrum in the two samples irra-
diated simultaneously (sample 1 in blue and sample 2 in purple), per meV.
Dashed lines correspond to the capture equivalent spectrum (per meV) of the
beam and each sample. Data corresponds to the beam in June 2018, with a total
capture equivalent flux of n cm s1.75 10 /th9 2 measured. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web
version of this article.)
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calculated with the McStas neutron transport software [17]. For dose
estimation, neutron kerma factors are calculated for ICRU-33 tissue
with H, C, N, O based on cross sections from ENDF/B-VII and photon
kerma factors from Seltzer X-ray [18] mass attenuation data. Final dose
components were calculated from the fluence provided by the MCNPX
simulation convoluted with the calculated neutron kerma factors [4].
Secondary fast neutrons created in nuclear reactions induced by the
charged particles produced by neutron captures in both Li and B re-
spectively [19] of the shielding are shown to contribute far less than 1%
to the dose (See Table 1). The effect of a non-perfect Charged Particle
Equilibrium (CPE) achieved, where about 20% of the dose from protons
after neutron captures in the cells is deposited outside the cell layer, is
included (for a cell layer of 15 μm thickness, the calculated effect
amounts to 18.5%). The doses are calculated for a nitrogen composition
of 4.6% (mass fraction) for skin cells [20].
In the simulations, photons from neutron capture are also trans-
ported and the gamma dose produced at the cells has been calculated,
as well as the pure neutron dose. The gamma dose, produced mainly
from captures on hydrogen in the culture medium and cells, is esti-
mated to be around 21% of the total physical dose for the first sample
and 30% for the second (values displayed in Table 2). This means a
great improvement with respect to previous in vitro measurements
performed at other facilities, e.g. at the thermal column of BMRR, from
where the reference values used in BNCT were obtained, where the
gamma component was greater than the thermal (called nitrogen) dose
component [5].
In addition to the neutron flux measurements with gold foils, the
relative doses obtained in the simulations were confirmed when results
of cuvette 1 irradiated for 40min (simulated dose of 2.51 Gy) were
compared with those from cuvette 2 irradiated for 75min (simulated
dose of 2.46 Gy). In Fig. 7, similar survival and proliferation data can be
seen for both cases.
The dose rate obtained allows performing cell survival experiments
for reasonable irradiation times. The effect of the gamma component
will be subtracted accordingly with the linear-quadratic model in order
to extract the pure neutron effect.
Fig. 4. Measured beam at sample1 position. The 3D profile is extracted from the
radiochromic films scanned. The figure and data correspond to the measured
results of a film irradiated for 80 s, compared to the simulated data in the
graphs. The deviation from the average flux along the x and y axis is re-
presented, with an error on the simulation of ± 0.02, shown with error-bars in
one of the points. Root-mean-square deviation (RMSD) is indicated (in both
cases, measured and simulation, it is less than 3%).
Fig. 5. Schematic cut view of the setup used in the experiments and simulations (left drawing) and a picture (right) of the irradiation holder placed at the exit of the
beam line with the cuvettes filled with cells and culture medium.
Table 1
Undesired dose component analysis to design the final set-up. First, gamma
dose at the sample 1 due to neutron capture in the different materials, and
second, fast dose on the sample 2 (nearest to beam stopper) due to neutron
captures in LiF of the beam stopper [19]. When there is only the beam and a
layer of cells, the gamma dose component is less than 1% of the total dose
(Table 2). By adding the culture media (necessary for the cells to survive), for
2mm of media, the gamma dose jumps to 12% of the total dose. The quartz
cuvette to contain the cells and the media increases the gamma dose component
to 19%. Finally, by adding the second quartz, to leverage beam time by irra-
diating two samples at same time, the gamma dose goes to 21% of the total
dose. The fast dose from neutron captures in Li in the beam stopper is negligible
when the beam stopper is at the real position, and remains negligible even
when the beam stopper is placed just after the sample 2. Uncertainties of the
dose calculations are explained in the caption of Table 2.
Set-up Gamma dose (Gy/h) in
cuvette 1
Beam+ cells 0.026
Beam+ cells+ 2mm culture media 0.446
Beam+ cells+ 2mm culture media+ quartz
cuvette
0.702
Beam+2 complete quartz cuvettes (real Set-up) 0.784
Set-up Fast Dose (Gy/h) in
cuvette 2
Beam stopper at 8.1 cm (real Set-up) 10−6
Beam stopper at 0.01 cm 10−4
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2.3. Cell culture and survival studies
A level 2 biological lab has been installed in the same instrument
hall as the PF1b beam line to facilitate the sample management. The
new lab and beam line are within 1min walking distance, thus enabling
high sample throughput per day.
For the neutron irradiations, 2x105 cells in 200 µl complete medium
are placed inside 2mm thick quartz cuvettes. After 24 h, cells are
naturally attached in one layer inside the quartz cuvettes. Before the
irradiation, the culture medium is replaced.
After the irradiation, clonogenic assays are performed. Cells are
detached with 1% trypsin-EDTA (Sigma-Aldrich, St Louis, MO, USA)
and suspended in complete culture medium. Cells are then seeded into
6-well plates at different densities, as the plating efficiency varies with
the cell line and the irradiation. In the example case of A375 cells, after
7–8 days, colonies were fixed with 90% ethanol at room temperature
and stained with crystal violet (1% w/v) for 30min. Crystal violet was
removed carefully, the plates were immersed in tap water to rinse off
the dye. Colonies containing more than 50 cells are counted and sur-
viving fractions are calculated. All assays are performed in triplicates.
Finally, in order to obtain results for a second biological end-point, a
cell proliferation assay can be also performed after irradiation by means
of the BrdU Cell Proliferation ELISA kit (Roche, Mannheim, Germany).
Briefly, A375 cells (1× 103/well) were seeded into 96-well plates and
grown for 96 h and proliferating cells were determined according to the
manufacturer‘s protocol.
The A375 cell line was kindly provided by Dr. Lucie Sancey
(Institute for Advanced Biosciences, Grenoble). Cells were cultured in
RPMI medium (HyClone, Logan, USA) containing 10% fetal bovine
serum (FBS; Gibco, California, USA), 1 μM L-glutamine (Gibco,
California, USA) and 100 IU/ml penicillin and 100 IU/ml streptomycin
(Sigma-Aldrich, St. Louis, USA) at 37 °C in a humidified 5% CO2, 95%
air incubator.
3. Example of application: A375 cell line
3.1. Survival after neutron irradiation by clonogenic assay
A set of irradiations from 15 to 82min were carried out which re-
sulted in doses in the range of 0.48–5.1 Gy. After each irradiation, a
clonogenic assay was performed. An example of the colony growth in
response to two different irradiation doses is shown in Fig. 6.
The survival was expressed according to the plating efficiency of the
control sample for each irradiation. Results in Fig. 7 show that, even at
low doses of less than 1 Gy, there was a strong effect with around 50%
of cells surviving. At a neutron fluence of 3.7×1012 n/cm2, which
corresponds to a dose of around 2.8 Gy, the survival fraction was 10%.
These results are an illustration of the strong effect of the low energy
neutron irradiation compared with that of the photon one where, in
most of cell lines, more than 4 Gy are required to reach a 10% of sur-
vival.
3.2. Cell proliferation after neutron irradiation
As a second biological end-point, we performed a BrdU assay which
shows all the cells that are viable and can proliferate. Proliferating
A375 cells at 96 h after neutron irradiation are shown in Fig. 7. There
was a strong decay in the amount of proliferative cells after 3 Gy irra-
diation. A 70% inhibition of cell proliferation was observed at the
highest dose.
A375 cells are known to be very resistant to X-ray radiation. For
example, in a recent study, 60% of viable cells were still found after
delivering 2 Gy of X-ray radiation, and nearly 40% of cells were viable
in response to 6 Gy [21]. From our data, it seems that neutron irra-
diation is more effective in reducing cell proliferation as, with doses of
around 4 Gy, the fraction of viable cells drops to less than 30%.
3.3. Determination of the thermal neutron RBE weighting factor
As the colony formation ability is the common biological endpoint
chosen for survival studies in radiobiology, the results from the clo-
nogenic assay have been chosen for deriving the RBE factor.
For the analysis, several assumptions are made: First, the photon
spectrum produced by the neutron beam has the same radiobiological
effectiveness as the photon spectrum used in gamma-ray irradiations,
for which results exist in the literature. Therefore, the parameters used
for the reference photon dose will be the same as those used for the
gamma component of the beam. Second, following the current form-
alism shown in Eq. (1), no synergies are involved, ergo the effects on
the cells are independent between different secondary particles. Third,
survival curves are fitted following the linear-quadratic model [22],
with the quadratic component neglected for the high LET component
(pure neutron).
Table 2
Dose rate delivered at the melanoma cells during the irradiations at the two positions. The statistical uncertainties from the fluence from Monte Carlo simulations are
less than 1% and the error of the kerma factor used to calculate the dose is less than 5% (ICRU recommendations). The good temporal stability of the beam and the
stable positioning of the samples add a systematic error of no more than 3%. The neutron shutter was operated manually which introduces a scatter in effective
irradiation time of 2% on average (up to 5% for the shortest irradiations). An assumed thickness variation of± 10% of the cell layer (13.5 to 16.5 μm) results in± 2%
uncertainty of the incomplete CPE correction of the thermal dose. The actual irradiation times are logged with 1 s resolution, but due to the nonlinear dose-effect
relationship we refrained from rescaling the results of slightly different irradiation times and rather consider this scatter as a statistical uncertainty in dose. This data
corresponds to the flux in June 2018. Data must be adapted depending on the actual capture flux during the irradiation cycle, which is determined with gold foil
measurements.
Sample Thermal neutron dose rate (Gy/h) Gamma dose rate (Gy/h) Fast neutron dose rate (Gy/h) Total dose rate (Gy/h)
Cells in cuvette 1 2.942 0.784 10−6 3.726
Cells in cuvette 2 1.374 0.588 10−6 1.962
Fig. 6. Colonies formed by A375 cells at 7 days after the irradiation. The
bottom row of samples received a lower dose than the top row. The increase in
the number of colonies, i.e. higher survival, is clearly observed, even though the
amount of cells seeded (number on the top of the first well) is less for the low
doses.
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With these assumptions, the total survival fraction S is assumed to
be the product of the two components S (photon survival) and Sn (pure
neutron survival):
= =S S S e e· ·n D D Dn n2 (2)
For removing the photon effect of the beam, we have evaluated for
each sample the pure neutron survival Sn from the experimental values
of S and making use of Eq, (2) with the following data for the radio-
biological photon parameters for A375 cells from Gómez-Millan et al.
[24]: = 0.187 ± 0.057 Gy−1 and = 0.035 ± 0.008 Gy−2.
The resulting Snvalues are displayed in Fig. 8. A fitting of an ex-
ponential function to these values has been done with the result of
n =0.93 ± 0.03 Gy−1. The fit is also illustrated in Fig. 8 (dotted
line).
The fit was computed using the Levenberg-Marquardt algorithm
[25]. The correlation coefficient was r= 0.998 and the reduced chi
squared gives 0.124. The good agreement of the values of Sn in log scale
with a linear function, characteristic of high LET radiation, shows the
adequacy of the removal of the photon effect.
In Table 3 we show the dose contributions received by the different
samples and the partial survival fractions.
In Fig. 9 we illustrate a comparison of the survival function in terms
of the total absorbed dose for the pure neutron irradiation obtained in
this work with the photon survival from the measurements of Gómez-
Millán et al. [24] and with the survival data obtained in the mixed field
beam. At a 1 Gy photon irradiation, the survival is around 80%, while
1 Gy of pure thermal neutron dose leads to a survival of less than 40%.
The data obtained at the ILL is in between these two cases, because the
dose is a mix of a contribution of thermal neutrons and a small
percentage of photons. For a certain survival fraction, by the compar-
ison of the dose of the curve following Sref and the curve following Sn,
the RBE can be obtained.
For obtaining the RBE factor wt it is necessary to compare the
photon and pure thermal neutron dose producing the same survival.
This is intrinsically dependent on the survival (i.e. on the dose itself)
and it is usually reported for different levels of survival. For a given Dn,
the RBE factor is given by =w D D/t ref n, , where D ref, denotes the re-
ference photon dose producing the same survival, that can be calculated
Fig. 7. Left: Survival fraction of the different samples of A375 cells after different irradiation times as a function of the neutron fluence. Then, survival data
corresponding to similar doses are grouped and represented as a function of the total absorbed dose, which includes the gamma dose component. Cells attached in
one layer inside quartz cuvettes were homogeneously irradiated and the surviving fraction was determined by clonogenic assay. Right: BrdU proliferation data at of
A375 cells 96 h after different irradiation times as a function of the neutron fluence. Data corresponding to similar doses are grouped like in the left graphs. Values are
expressed as absorbance given by the plate reader, normalized to control (non irradiated cells). Raw and processed data are available via [23]. Errors in dose
correspond to standard deviation (SD) due to differences on irradiation times. Errors in survival and absorbance correspond to the highest error in between SD and
the error propagation.
Fig. 8. Pure neutron survival fraction Sn data, extracted from the experimental
survival as mentioned in the text, displayed in logarithmic scale in terms of the
thermal neutron dose. The linear fit displayed with the dashed line gives a
radiobiological coefficient of αn= 0.93 ± 0.03 Gy−1 for thermal neutrons.
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(once knowing , and n) from
= =S e eRBE D D Dref ref n n, ,2 (3)
By using the radiobiological coefficients of above, we find the re-
sults displayed in Table 4 for different common survival choices. Zero-
dose limiting value, also called RBEmax or Wt , is included, which cor-
responds to the ratio between alpha coefficients: =W /t n, . For a
particular application, the RBE value chosen should correspond to the
actual thermal neutron dose Dn according to the treatment plan.
In reported BNCT treatments for melanoma [26], the mean thermal
neutron dose is about 2.3 Gy (range of 1.3–3.5 Gy). From the observa-
tion of the table, this corresponds to values of the RBE in an interval of
2.4–2.8, close to the values used for the thermal dose both at skin and
tumor in the melanoma clinical trials: 2.5 for the Kyoto trials [26] or
3.0 for the Argentinian ones [27], and smaller than the value of 3.2
used in brain tumor clinical trials [6].
In these data, the uncertainty from the fitting is less than 6%.
However, the resulting uncertainties for the RBE values are of the order
of 30%, due to the 30% uncertainty of the photon α coefficient taken
from the literature. Therefore this procedure allows the collection of
accurate data for low-energy neutrons so that more precise RBE factors
can be calculated, provided photon data of similar precision become
available.
4. Conclusions and outlook
The PF1b line at the ILL reactor provides a high flux of cold neu-
trons, with a low gamma component and the absence of an epithermal
dose due to the bent neutron guide. This results in an ideal beam for
measuring the radiobiological effect of thermal neutrons. In addition,
with the new installation of a level 2 biological laboratory inside the
neutron guide hall, it is possible to handle mammalian cells and carry
out multiple irradiations and measurements per day, contributing to
better statistics.
New data for the damage of thermal neutrons in melanoma cells
have been obtained following the explained procedure. The RBE of
thermal neutrons for this cell type can be calculated for different doses
from Fig. 9. For BNCT melanoma treatments, a RBE factor from Table 4
can be chosen according to the thermal dose applied.
The developed setup at PF1B-ILL paves the way to extensive mea-
surements, following the same procedure for other cell lines of both,
tumor and healthy cells. An experimental campaign has been started at
ILL for this purpose. This can be of interest not only for BNCT but also
for the extraction of data for radioprotection purposes. As the boron
dose in BNCT is produced by thermal neutrons, in this campaign the
measurement of the boron RBE factor (compound-dependent CBE) for
different compounds is also foreseen, using the same setup and proce-
dure described here.
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Values for each absorbed dose component of the irradiation (for each cuvette position and irradiation time): Dn for thermal neutrons, Dγ for the photons and D for the
total. S is the final survival fraction of the A375 samples. Survival correponding to photon irradiation, Sγ, described with Gómez-Millan et al. (2012) parameters [24].
Values for the survival fraction corresponding to the effect of just the thermal neutron component of the beam, Sn, calculated using Eq. (2). Errors of D and S from
measurements, as explained in Fig. 7 caption. Errors for all the other components by error propagation.
Sample D(Gy) D (Gy) Dn(Gy) S S Sn
Control 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000
Cuvette 2, 15min 0.552 ± 0.013 0.165 ± 0.004 0.386 ± 0.009 0.559 ± 0.220 0.969 ± 0.010 0.577 ± 0.233
Cuvette 1, 15min 1.008 ± 0.023 0.212 ± 0.005 0.796 ± 0.018 0.423 ± 0.239 0.960 ± 0.013 0.441 ± 0.255
Cuvette 2, 40min 1.510 ± 0.010 0.452 ± 0.003 1.057 ± 0.007 0.408 ± 0.148 0.912 ± 0.026 0.447 ± 0.206
Cuvette 2, 60min 2.243 ± 0.001 0.672 ± 0.000 1.571 ± 0.001 0.274 ± 0.175 0.868 ± 0.036 0.315 ± 0.215
Cuvette 2, 75min 2.759 ± 0.019 0.580 ± 0.004 2.179 ± 0.015 0.101 ± 0.005 0.887 ± 0.033 0.114 ± 0.066
Cuvette 1, 40min 2.807 ± 0.001 0.841 ± 0.000 1.966 ± 0.001 0.093 ± 0.002 0.834 ± 0.045 0.111 ± 0.077
Cuvette 1, 60min 4.100 ± 0.002 0.862 ± 0.000 3.239 ± 0.002 0.047 ± 0.028 0.829 ± 0.046 0.057 ± 0.037
Cuvette 1, 75min 5.131 ± 0.002 1.079 ± 0.000 4.052 ± 0.001 0.019 ± 0.004 0.785 ± 0.056 0.024 ± 0.012
Fig. 9. Survival data from the A375 cells irradiated at ILL fitted with the sur-
vival function S. Sref and Sn correspond to survival curves due to the isolated
effect of photon and thermal neutron irradiation respectively, both described
with the parameters included in the text ( and for photons and n for
neutrons).
Table 4
RBE values obtained for different survival fractions by the ratio of the reference
photon dose and the neutron dose. Errors performed by error propagation.
Survival (%) Dn(Gy) Error Dn D ref, (Gy) Error
D ref,
wt(RBE) Error wt
100 – limit Limit→ 0 Limit→ 0 4.95 (Wt) 1.81
75 0.311 0.011 1.247 0.029 4.01 0.39
50 0.749 0.025 2.519 0.027 3.36 0.67
37 1.075 0.037 3.290 0.025 3.06 0.68
25 1.498 0.051 4.166 0.024 2.78 0.65
10 2.488 0.085 5.868 0.023 2.36 0.58
5 3.238 0.110 6.958 0.022 2.15 0.54
1 4.977 0.169 9.106 0.021 1.83 0.47
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.ill.fr/10.5291/ILL-DATA.3-07-376.
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